ALLMedicine™ Evans Syndrome Center

Jan 21st, 2023 - Primary immune thrombocytopenia (ITP) in adult patients typically presents as a repeatedly relapsing disease in need of multiple lines of therapy. Here we report the clinical courses of two patients, an 82-year-old female and a 54-year-old male, w...

Dec 30th, 2022 - The boundaries between myelodysplastic syndromes (MDS) and immune-mediated cytopenias are often difficult to establish and both conditions may benefit from immunosuppressive therapy. The optimal timing and doses of immunosuppressants are largely u...

Dec 21st, 2022 - Pure red cell aplasia (PRCA) is a rare normocytic normochromic anemia with reticulocytopenia, characterized by a reduction of erythroid precursors from the bone marrow, could be divided into congenital and acquired PRCA according to pathogenesis. ...

Dec 10th, 2022 - Hematologic manifestations are common in systemic lupus erythematosus (SLE), either at initial presentation or during the course of the disease, but data regarding their natural history are scarce. To describe the characteristics, treatments, and ...

Nov 10th, 2022 - Approach Considerations Standard blood studies for the workup of suspected hemolytic anemia include the following: Complete blood cell count (CBC) Peripheral blood smear Serum lactate dehydrogenase (LDH) Serum haptoglobin Indirect bilirubin Hemoly...

Dec 21st, 2022 - Pure red cell aplasia (PRCA) is a rare normocytic normochromic anemia with reticulocytopenia, characterized by a reduction of erythroid precursors from the bone marrow, could be divided into congenital and acquired PRCA according to pathogenesis. ...

Jul 19th, 2022 - This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult ITP patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag t...

May 11th, 2022 - This is a prospective, open-label, nonrandomized, multicenter clinical trial aiming at comparing the efficacy and safety of combined use of eltrombopag with low-dose rituximab vs. the best available therapy（BAT）in adult immune thrombocytopenia (...

Oct 13th, 2021 - Glucocorticoids are the first-line treatment of warm AIHA. The overall response is 70-90%, but 10% to 20% patients are refractory to GCs and more than 50% patients will relapse after GCs tapering or cessation. Anti-CD20 monoclonal antibody is the ...

Jul 6th, 2021 - Pure red cell aplasia (PRCA) is a rare normocytic normochromic anemia with reticulocytopenia, characterized by a reduction of erythroid precursors from the bone marrow, could be divided into congenital and acquired PRCA according to pathogenesis. ...

Oct 11th, 2022 - Transcript: Howard Liebman, MD: I think you’ve got FcRn inhibitors. What people must understand is that the so-called neonatal receptor is not just involved in transplanting antibodies to the infant, although it’s important in that. It also is ne...

Aug 11th, 2022 - Transcript: Morey Blinder, MD:Let’s move on to the next drug in this family of potential second-line therapies. Let’s talk about fostamatinib, the newest of these second-line therapies. Where does it fit in? I’ll just share my experience, which i...

Aug 11th, 2022 - Transcript: Morey Blinder, MD: Hello, and welcome to this OncLive Peer Exchange®, advances in the treatment and management of immune thrombocytopenic purpura, or ITP. I’m Dr Morey Blinder from Washington University School of Medicine in St Loui...

Apr 13th, 2022 - An investigational oral Bruton's tyrosine kinase (BTK) inhibitor was tolerable and yielded rapid and durable responses in pretreated patients with immune thrombocytopenia (ITP), according to results of an open-label phase I/II trial. In the 60-pat...

Dec 4th, 2020 - Shirley Michelle Shiller, DO Regarding precision medicine in gastrointestinal (GI) cancers, pathologists are working to determine which patient populations should undergo which molecular tests. Colorectal Cancer In a presentation during the 201...